Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Feasibility Study of the ReLeaf Catheter System (ReLeaf)

26. mars 2018 oppdatert av: Intervene, Inc.

A Feasibility Study of the InterVene ReLeaf Catheter System in the Creation of Tissue Leaflets in the Femoral and/or Popliteal Vein

This study is designed to evaluate the safety and technical feasibility of the ReLeaf Catheter System in the creation of one or more tissue leaflets in the femoral and/or popliteal vein in subjects with chronic venous insufficiency and who meet the protocol entry criteria.

Studieoversikt

Status

Avsluttet

Intervensjon / Behandling

Detaljert beskrivelse

The ReLeaf catheter system is intended for the creation of tissue leaflets in the deep veins where existing valve structures are no longer healthy and effectively moving blood.

This study aims to treat subjects with a documented history of symptomatic chronic venous insufficiency in whom compression therapy for at least 6 months, combined with superficial venous and/or perforator surgery have failed to obtain clinical improvement.

This clinical trial is designed to evaluate the safety and technical feasibility of the ReLeaf Catheter System in the creation of one or more tissue leaflets in the femoral and/or popliteal vein in subjects with chronic venous insufficiency and who meet the protocol entry criteria.

Studietype

Intervensjonell

Registrering (Faktiske)

2

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Auckland, New Zealand
        • Auckland City Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • History of symptomatic chronic venous insufficiency subjects, clinical category CEAP 3 or greater.
  • History of failed compression therapy (of at least 6 months), combined with superficial venous or perforator surgery.
  • Femoral and/or popliteal venous reflux of ≥ 1.0 seconds.
  • Deep system reflux with Kistner classification grade 2 or higher.
  • 18 years of age or older at the time of consent.
  • Willing and able to sign the Ethics Committee (EC) approved informed consent form.
  • Willing to comply with follow-up evaluations and protocols.

Exclusion Criteria:

  • In the Investigator's opinion, venous outflow obstruction that would inhibit adequate flow away from valve site.
  • Obstructive features in the femoral or popliteal vein below the proposed tissue leaflet creation site, which, in the Investigator's opinion, will not allow for sufficient blood flow to the tissue leaflet creation site.
  • Deep venous system intervention within 6 months of consent.
  • Obstructive features or irregularly small luminal diameter in the femoral vein which, in the opinion of the Investigator, will prohibit access to a tissue leaflet creation site.
  • Prior deep vein valve surgical intervention in the ipsilateral limb.
  • Ankle arthrodesis with secondary muscle atrophy or severely limited ambulation.
  • Limb-threatening circulatory compromise.
  • Contraindications to anticoagulation therapy that cannot be medically controlled.
  • History of symptomatic pulmonary embolism.
  • Acute venous thromboembolism within 3 months of consent.
  • Comorbidity risks which, in the opinion of the Investigator, limit longevity or likelihood of complying with protocol follow up.
  • General contraindications to surgery or the use of anesthesia.
  • Uncontrolled heart failure, or NYHA Class III or IV heart failure.
  • Open Cardiac surgery (e.g. ventriculotomy, atriotomy) within the past 6 months of consent (Interventional procedures such as stenting or PTCA do not apply.)
  • Chronic Kidney Disease with creatinine level of 2mg/dL or higher.
  • Active systemic infection or sepsis.
  • Pregnant or lactating (positive pregnancy test, women of childbearing potential must be tested).
  • Appropriate vascular access is precluded.
  • Subject is enrolled in any other clinical study that, in the opinion of the Investigator, may conflict with this study or compromise study results.
  • Subject is considered at high risk for non-compliance with the protocol (e.g., inaccessible for follow-up).
  • Other invasive surgical procedure within the last 90 days that in the Investigator's opinion would interfere with the study procedure or results.
  • History of stroke within the last 6 months.
  • Subject is incarcerated or will be incarcerated during the course of the study.
  • Untreated significant superficial venous incompetence

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Treatment
Subject to undergo the ReLeaf study procedure.
The ReLeaf catheter is expected to enable a physician to create tissue leaflets that, in turn, generate a valve effect in the deep veins of the legs.
Andre navn:
  • Tissue Leaflet Creation, Creation of Valve-like Effect

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Technical Feasibility
Tidsramme: Day 0
Technical feasibility will be evaluated as the ability of the ReLeaf Catheter System to access the target site and successfully modify tissue as confirmed by, and in the opinion of, the Investigator. Successful target site access and confirmed tissue modification will be used as a measure of technical feasibility.
Day 0
Safety (The number of SAEs directly attributable to the study device will be used as a measure of safety)
Tidsramme: Day 30
Safety will be evaluated as freedom from serious adverse events directly attributed to the investigational device. The number of SAEs directly attributable to the study device will be used as a measure of safety.
Day 30

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Efficacy
Tidsramme: Day 365
Subsequent efficacy of the treatment following successful creation of the tissue leaflet(s). This will be measured through an assessment of tissue leaflet creation and the tissue leaflets ability to impact blood flow over the course of time.
Day 365
Durability
Tidsramme: Day 365
Long-term durability of the tissue leaflet(s). Confirmation of tissue leaflet existence over time will be used to assess the durability of the tissue leaflet.
Day 365
Long-term Safety (Long-term safety will be measured by freedom from SAEs directly attributable to the study device)
Tidsramme: Day 365
Further long-term safety data will be collected, analyzed and reported through the end of the study. Long-term safety will be measured by freedom from SAEs directly attributable to the study device.
Day 365

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

9. september 2015

Primær fullføring (Faktiske)

8. oktober 2016

Studiet fullført (Faktiske)

5. juni 2017

Datoer for studieregistrering

Først innsendt

26. mai 2015

Først innsendt som oppfylte QC-kriteriene

2. juni 2015

Først lagt ut (Anslag)

3. juni 2015

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. mars 2018

Siste oppdatering sendt inn som oppfylte QC-kriteriene

26. mars 2018

Sist bekreftet

1. mars 2018

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CLP-0001

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Kronisk venøs insuffisiens

Kliniske studier på ReLeaf

3
Abonnere